elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Lutetium
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Application
keyword
Lutetium
RIS
0.020
(Research Intensity Score)
Papers
4548
Top papers
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 · 2750 citations
Assessing sustainable Lutetium(III) ions adsorption and recovery using novel composite hybrid nanomaterials
2022 · 331 citations
Size-dependent lanthanide energy transfer amplifies upconversion luminescence quantum yields
2024 · 163 citations
A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements
2023 · 202 citations
Enhanced rare-earth separation with a metal-sensitive lanmodulin dimer
2023 · 193 citations
Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial)
2024 · 100 citations
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
2022 · 237 citations
RETRACTED ARTICLE: Evidence of near-ambient superconductivity in a N-doped lutetium hydride
2023 · 163 citations
Transition Metal Compounds
2025 · 52 citations
Newest papers
PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions
2026 · 5 citations
Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles
2026 · 4 citations
Transition Metal Compounds
2025 · 52 citations
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
2025 · 38 citations
Potential Applications of Rare Earth Metal Nanoparticles in Biomedicine
2025 · 44 citations
Small Organic Carbonic Anhydrase IX Ligands from DNA-Encoded Chemical Libraries for Tumor-Targeted Delivery of Radionuclides
2025 · 20 citations
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
2025 · 13 citations
Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177
2025 · 17 citations
177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
2025 · 16 citations
Browse all papers →
Lutetium's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Lutetium's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link